Resveratrol - pills to replace a healthy diet?

British Journal of Clinical Pharmacology

Volumn 72, Issue 1, 2011, Pages 27-38

  Chachay, Veronique S ^a,c   Kirkpatrick, Carl M J ^a,b   Hickman, Ingrid J ^a,c   Ferguson, Maree ^c   Prins, Johannes B ^a,d   Martin, Jennifer H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Bioactive food compounds; Nutraceuticals; Nutrapharmacology; Polyphenols; Resveratrol

Indexed keywords

GRAPEFRUIT EXTRACT; PROTEIN KINASE; RESVERATROL; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL CYCLE; CHEMOPROPHYLAXIS; DIET; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RESEARCH; DRUG TOLERABILITY; FATTY LIVER; FOOD COMPOSITION; HEART PROTECTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRAPHARMACOLOGY; OBESITY; OXIDATION; OXIDATIVE STRESS; PHARMACODYNAMICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

AGING; ANTIOXIDANTS; CHRONIC DISEASE; DIET; DIETARY SUPPLEMENTS; FOOD; HUMANS; STILBENES;

EID: 79958761363     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03966.x     Document Type: Review

References (99)

1. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010; 30: 173-99.
2. Prasad S, Phromnoi K, Yadav VR, Chaturvedi MM, Aggarwal BB. Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 2010; 76: 1044-63.
3. Anand P, Kunnumakara A, Sundaram C, Harikumar K, Tharakan S, Lai O, Sung B, Aggarwal B. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 2008; 25: 2097-116.
4. Cave M, Hurt R, Frazier T, Matheson P, Garrison R, McClain C, McClave S. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 2008; 23: 16-34.
5. Jang M, Cai L, Udeani G, Slowing K, Thomas C, Beecher C, Fong H, Farnsworth N, Kinghorn A, Mehta R. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
6. Brown L, Kroon P, Das D, Das S, Tosaki A, Chan V, Singer M, Feick P. The biological responses to resveratrol and other polyphenols from alcoholic beverages. Alcohol Clin Exp Res 2009; 33: 1513-23.
7. Morris B. Calorie restriction mimetics and aging. In: Calorie Restriction, Aging Longevity, eds Everitt AV, Rattan SIS, Couteur DG, de Cabo R. The Netherlands: D Springer Science+Business Media B.V., 2010; 141-75.
8. Kroon A, Iyer A, Chunduri P, Chan V, Brown L. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem 2010; 17: 2442-55.
9. Orallo F. Comparative studies of the antioxidant effects of cis-and trans-resveratrol. Curr Med Chem 2006; 13: 87-98.
10. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339: 1523-26.
11. Criqui M, Ringel B. Does diet or alcohol explain the French paradox? Lancet 1994; 344: 1719-23.
12. Siemann E, Creasy L. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 1992; 43: 49-52.
13. Frankel E, German J, Kinsella J, Parks E, Kanner J. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341: 454-57.
14. Gresele P, Pignatelli P, Guglielmini G, Carnevale R, Mezzasoma A, Ghiselli A, Momi S, Violi F. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 2008; 138: 1602-08.
15. Natella F, Ghiselli A, Guidi A, Ursini F, Scaccini C. Red wine mitigates the postprandial increase of LDL susceptibility to oxidation. Free Radic Biol Med 2001; 30: 1036-44.
16. Paul B, Masih I, Deopujari J, Charpentier C. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J Ethnopharmacol 1999; 68: 71-6.
17. Shakibaei M, Harikumar K, Aggarwal B. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009; 53: 115-28.
18. Csiszar A. Anti inflammatory effects of resveratrol: possible role in prevention of age related cardiovascular disease. Ann NY Acad Sci 2011; 1215: 117-22.
19. Agarwal B, Baur JA. Resveratrol and life extension. Ann NY Acad Sci 2011; 1215: 138-43.
20. Wu JM, Hsieh T. Resveratrol: a cardioprotective substance. Ann NY Acad Sci 2011; 1215: 16-21.
21. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci 2011; 1215: 1-8.
22. Pezzuto J. Resveratrol as an inhibitor of carcinogenesis. Pharm Biol 2008; 46: 443-573.
23. Cantó C, Jiang L, Deshmukh A, Mataki C, Coste A, Lagouge M, Zierath J, Auwerx J. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab 2010; 11: 213-19.
24. Um J, Park S, Kang H, Yang S, Foretz M, McBurney M, Kim M, Viollet B, Chung J. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59: 554-63.
25. Pervaiz S, Holme A. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009; 11: 2851-97.
26. Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides-Two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008; 52: 549-57.
27. Caruso F, Tanski J, Villegas-Estrada A, Rossi M. Structural basis for antioxidant activity of trans-resveratrol: ab initio calculations and crystal and molecular structure. J Agric Food Chem 2004; 52: 7279-85.
28. Langcake P, Cornford C, Pryce R. Identification of pterostilbene as a phytoalexin from Vitis vinifera leaves. Phytochemistry 1979; 18: 1025-27.
29. Langcake P, Pryce R. The production of resveratrol by Vitis vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol 1976; 9: 77-86.
30. Lyons M, Yu C, Toma R, Cho S, Reiboldt W, Lee J, van Breemen R. Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem 2003; 51: 5867-70.
31. Brown V, Patel K, Viskaduraki M, Crowell J, Perloff M, Booth T, Vasilinin G, Sen A, Schinas A, Piccirilli G. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003-11.
32. Cottart C, Nivet Antoine V, Laguillier Morizot C, Beaudeux J. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010; 54: 7-16.
33. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron D. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49: 449-54.
34. Chow H, Garland L, Hsu C, Vining D, Chew W, Miller J, Perloff M, Crowell J, Alberts D. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 2010; 3: 1168-75.
35. Gescher A, Steward W. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prevent 2003; 12: 953-57.
36. Walle T. Bioavailability of resveratrol. Ann NY Acad Sci 2011; 1215: 9-15.
37. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties (review). Curr Drug Metab 2009; 10: 530-46.
38. Kuhnle G, Spencer J, Chowrimootoo G, Schroeter H, Debnam E, Srai S, Rice-Evans C, Hahn U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 2000; 272: 212-17.
39. Vaz-da-Silva M, Loureiro A, Falcao A, Nunes T, Rocha J, Fernandes-Lopes C, Soares E, Wright L, Almeida L, Soares-da-Silva P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther 2008; 46: 564-70.
40. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi P, Fogliano V, Marchelli R. Bioavailability of trans resveratrol from red wine in humans. Mol Nutr Food Res 2005; 49: 495-504.
41. Walle T, Hsieh F, DeLegge M, Oatis J, Walle U. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-82.
42. Wenzel E, Somoza V. Metabolism and bioavailability of trans resveratrol. Mol Nutr Food Res 2005; 49: 472-81.
43. Almeida L, Vaz da Silva M, Falcão A, Soares E, Costa R, Loureiro A, Fernandes Lopes C, Rocha J, Nunes T, Wright L. Pharmacokinetic and safety profile of trans resveratrol in a rising multiple dose study in healthy volunteers. Mol Nutr Food Res 2009; 53: 7-15.
44. Boocock D, Faust G, Patel K, Schinas A, Brown V, Ducharme M, Booth T, Crowell J, Perloff M, Gescher A. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prevent 2007; 16: 1246-52.
45. Patel K, Brown V, Jones D, Britton R, Hemingway D, Miller A, West K, Booth T, Perloff M, Crowell J. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010; 70: 7392-99.
46. Calamini B, Ratia K, Malkowski M, Cuendet M, Pezzuto J, Santarsiero B, Mesecar A. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 2010; 429: 273-82.
47. Hoshino J, Park E, Kondratyuk T, Marler L, Pezzuto J, van Breemen R, Mo S, Li Y, Cushman M. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 2010; 53: 5033-43.
48. Jannin B, Menzel M, Berlot J, Delmas D, Lançon A, Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004; 68: 1113-18.
49. Lu Z, Zhang Y, Liu H, Yuan J, Zheng Z, Zou G. Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J Fluoresc 2007; 17: 580-87.
50. Christensen K, Doblhammer G, Rau R, Vaupel J. Ageing populations: the challenges ahead. Lancet 2009; 374: 1196-208.
51. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
52. Dixon J. The effect of obesity on health outcomes. Mol Cell Endocrinol 2010; 316: 104-08.
53. Reuter S, Gupta S, Chaturvedi M, Aggarwal B. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49: 1603-16.
54. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635: 1-8.
55. Harikumar K, Aggarwal B. A multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7: 1020-35.
56. Baur J, Sinclair D. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
57. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009; 2: 409-18.
58. Harikumar K, Kunnumakkara A, Sethi G, Diagaradjane P, Anand P, Pandey M, Gelovani J, Krishnan S, Guha S, Aggarwal B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 2010; 127: 257-68.
59. Csiszar A, Labinskyy N, Pinto J, Ballabh P, Zhang H, Losonczy G, Pearson K, De Cabo R, Pacher P, Zhang C. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297: H13-20.
60. Csiszar A, Wang M, Lakatta E, Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-{kappa} B. J Appl Physiol 2008; 105: 1333-41.
61. Das S, Das D. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovas Drug Discov 2007; 2: 133-38.
62. Baur J, Pearson K, Price N, Jamieson H, Lerin C, Kalra A, Prabhu V, Allard J, Lopez-Lluch G, Lewis K. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
63. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 [alpha]. Cell 2006; 127: 1109-22.
64. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008; 29: 698-706.
65. Pearson K, Baur J, Lewis K, Peshkin L, Price N, Labinskyy N, Swindell W, Kamara D, Minor R, Perez E. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8: 157-68.
66. Rivera L, Morón R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009; 77: 1053-63.
67. Dal-Pan A, Blanc S, Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 2010; 10: 1-10.
68. Shakibaei M, Csaki C, Nebrich S, Mobasheri A. Resveratrol suppresses interleukin-1 [beta]-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008; 76: 1426-39.
69. Rocha-González H, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther 2008; 14: 234-47.
70. Markus M, Morris B. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 2008; 3: 331-39.
71. de la Lastra C, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007; 35: 1156-60.
72. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 2009; 20: 443-52.
73. Das M, Das D. Resveratrol and cardiovascular health. Mol Aspects Med 2010; 31: 503-12.
74. Bhat K, Kosmeder J, Pezzuto J. Biological effects of resveratrol. Antioxid Redox Signal 2001; 3: 1041-64.
75. Lekakis J, Rallidis L, Andreadou I, Vamvakou G, Kazantzoglou G, Magiatis P, Skaltsounis A, Kremastinos D. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005; 12: 596-600.
76. Zern T, Wood R, Greene C, West K, Liu Y, Aggarwal D, Shachter N, Fernandez M. Grape polyphenols exert a cardioprotective effect in pre-and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr 2005; 135: 1911-17.
77. Huang PH, Chen YH, Tsai HY, Chen JS, Wu TC, Lin FY, Sata M, Chen JW, Lin SJ. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. Arterioscler Thromb Vasc Biol 2010; 30: 869-77.
78. Wong R, Howe P, Buckley J, Coates A, Kunz I, Berry N. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2010; Epub ahead of print. doi: 10.1016/j.numecd.2010.03.003.
79. Holcombe R. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 2009; 1: 25-37.
80. Martinez M, Hope C, Planutis K, Planutiene M, Pontello A, Duarte B, Albers C, Holcombe R. Dietary grape-derived resveratrol for colon cancer prevention. J Clin Oncol 28:15s, 2010 (suppl; abstr 3622).
81. Ibrahim Y, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004; 14: 261-69.
82. Ghanim H, Sia C, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010; 95: E1-E8.
83. Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, Chaudhuri A, Dandona P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab 2011; 96: Published online ahead of print.
84. Kennedy D, Wightman E, Reay J, Lietz G, Okello E, Wilde A, Haskell C. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010; 91: 1590-97.
85. Szekeres T, Fritzer-Szekeres M, Saiko P, Jäger W. Resveratrol and resveratrol analogues - structure - activity relationship. Pharm Res 2010; 27: 1042-48.
86. Wang LX, Heredia A, Song H, Zhang Z, Yu B, Davis C, Redfield R. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti HIV activity. J Pharm Sci 2004; 93: 2448-57.
87. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-61.
88. Burns J, Yokota T, Ashihara H, Lean M, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002; 50: 3337-40.
89. Goldberg D, Yan J, Ng E, Diamandis E, Karumanchiri A, Soleas G, Waterhouse A. A global survey of trans-resveratrol concentrations in commercial wines. Am J Enol Vitic 1995; 46: 159-65.
90. Wang Y, Catana F, Yang Y, Roderick R, van Breemen R. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem 2002; 50: 431-35.
91. Rimando A, Kalt W, Magee J, Dewey J, Ballington J. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem 2004; 52: 4713-19.
92. Wang S, Chen C, Wang C, Chen P. Resveratrol content in strawberry fruit is affected by preharvest conditions. J Agric Food Chem 2007; 55: 8269-74.
93. Wang S, Chen C, Sciarappa W, Wang C, Camp M. Fruit quality, antioxidant capacity, and flavonoid content of organically and conventionally grown blueberries. J Agric Food Chem 2008; 56: 5788-94.
94. Sanders T, McMichael JR, Hendrix K. Occurrence of resveratrol in edible peanuts. J Agric Food Chem 2000; 48: 1243-46.
95. Sobolev V, Cole R. trans-Resveratrol content in commercial peanuts and peanut products. J Agric Food Chem 1999; 47: 1435-39.
96. Hurst W, Glinski J, Miller K, Apgar J, Davey M, Stuart D. Survey of the trans-resveratrol and trans-piceid content of cocoa-containing and chocolate products. J Agric Food Chem 2008; 56: 8374-78.
97. Udenigwe C, Ramprasath V, Aluko R, Jones P. Potential of resveratrol in anticancer and anti inflammatory therapy. Nutr Rev 2008; 66: 445-54.
98. Counet C, Callemien D, Collin S. Chocolate and cocoa: new sources of trans-resveratrol and trans-piceid. Food Chem 2006; 98: 649-57.
99. Nunes T, Almeida L, Rocha J, Falcão A, Fernandes-Lopes C, Loureiro A, Wright L, Vaz-da-Silva M, Soares-da-Silva P. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J Clin Pharmacol 2009; 49: 1477-82.